iFlix, a rival of Netflix in Southeast Asia, has received $45 million in investment from U.K. broadcaster Sky. iFlix is an online streaming service that operates in Malaysia, Thailand and the Philippines and charges around $3 per month. Sky has said that the deal is strategic, and the two companies will work together to identify future areas of collaboration. “iflix has quickly established itself as Southeast Asia’s most exciting and fastest-growing streaming TV service. There are lots of opportunities for Sky and iflix to work together and share expertise as both companies continue to expand,” Andrew Griffith, Sky’s Group CFO, said in a statement.
Data analysis software provider Attivio, has announced $31 million in financing. The company has now raised a total of $102 million from its backers Oak Investment Partners, General Electric Pension Trust, Tenth Avenue Holdings, and Per-Olof Soderberg. “We had a watershed year in 2015,” said Stephen Baker, CEO of Attivio. “We launched Data Source Discovery for the BI market to radically reduce the time it takes to prepare data for analysis,” continued Baker. “Meanwhile, two top analyst firms separately acknowledged us as a leader in the enterprise search market, which is where our journey began. We’re uniquely positioned to help enterprises gain immediate visibility into all the right information.”
OneSpace, a virtual workplace platform, has completed a $9 million Series B funding round led by Lewis & Clark Ventures. The company will use the funds to expand its product suite and anticipates launching a software-as-a-service offering later this year. “Since 2012, our team’s mission has been to create a best-in-class platform for accessing and managing cloud-based talent,” said Stephanie Leffler, CEO of OneSpace. “We have proven our technology and we’re now ready to put the power of our platform in the hands of enterprises who are, by far, the largest buyers of flexible talent.”
Capella Bioscience, which works in therapeutic antibody discovery, has closed a $15.5 million Series A financing round. Advent Life Sciences, Medicxi Ventures and Osage University Partners provided the funding. “Our investment to support the development of antibodies against a variety of high value targets at Capella is based on strong scientific research, combined with an experienced and capable drug development team,” commented Raj Parekh of Advent Life Sciences. “We look forward to working with the Company to translate its research into important new medicines.”